{
}
UBS has upgraded its price target for Nemetschek shares from 98 to 115 euros but downgraded the stock from "Buy" to "Neutral" due to its strong performance, indicating that future surprises in 2025 are limited and the shares are highly valued. The analysis highlights that much of the potential is already reflected in the current price.
UBS has maintained a 'Neutral' rating for Bechtle, setting a target price of 44.60 euros, citing strong cash flow as a positive factor. Analyst Michael Briest noted that the share price reaction will likely hinge on the upcoming conference call. Bechtle has seen a remarkable 103% gain since its initial recommendation.
UBS has maintained its 'Buy' rating for Microsoft, setting a target price of $500. Analyst Karl Keirstead highlighted investor concerns regarding data center capacity, the financial impact of OpenAI, and the growth of Azure and M365 Cloud, but remains optimistic due to a positive outlook for 2025. Microsoft has seen a remarkable 311% increase since its initial recommendation.
UBS has maintained a "Neutral" rating for Apple, setting a price target of $236. Analyst David Vogt noted a 14% year-on-year increase in App Store sales for October, despite challenging comparisons. Apple has seen significant growth, gaining 11,187% since its first recommendation.
UBS has maintained a "Neutral" rating on Qiagen with a target price of 50 euros following the company's quarterly results, which surpassed expectations due to strong organic sales growth in diagnostics. However, the outlook for the biopharma sector indicates a slower recovery, and there are doubts about Qiagen's ability to match competitors' growth rates.
UBS has maintained a 'Neutral' rating for Novo Nordisk with a target price of 1100 Danish crowns. Despite the company's forecast of high growth for 2025, UBS's estimates are lower than market expectations, leading to a notable fluctuation in share prices following the announcement.
UBS has maintained a "Neutral" rating for Siemens Healthineers, setting a target price of 51 euros. Analyst Graham Doyle noted that while the fourth fiscal quarter was solid, the profit target for 2025 fell short of expectations, suggesting a more cautious planning approach may be beneficial.
UBS has maintained a 'Sell' rating for AstraZeneca, setting a target price of 11,300 pence ahead of the company's quarterly results. Analyst Matthew Weston noted that the forecasts align closely with consensus estimates.
UBS has reduced its price target for BASF from 48 to 47 euros while maintaining a "Neutral" rating. Analyst Geoff Haire noted that sales volumes have improved for the first time since Q4 2021, but challenges remain due to rising fixed costs, sluggish automotive market growth, and a stagnant economic environment.
UBS has reduced its price target for Aixtron from €20.90 to €14.90 following the company's quarterly results, maintaining a "Neutral" rating. Analyst Madeleine Jenkins anticipates a delayed market recovery in 2025, leading to significant cuts in earnings forecasts for 2025 and 2026, citing a lack of positive price drivers for the semiconductor supplier.
Hubert Dichtl
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
UBS downgrades Nemetschek to neutral while raising price target to 115 euros
07:15 11.11.2024
UBS maintains neutral rating for Bechtle with target price of 44.60 euros
09:04 08.11.2024
ubs maintains buy rating for microsoft with target price of 500 dollars
United States Dollar
Microsoft Corporation
USA
Hubert Dichtl
Warren Buffet
Thomas Müller
Karl Keirstead
Show more
10:33 07.11.2024
UBS maintains neutral rating on Apple with price target of 236 dollars
10:31 07.11.2024
UBS maintains neutral rating on Qiagen with target price of 50 euros
08:20 07.11.2024
ubs maintains neutral rating for novo nordisk with target price of 1100 kroner
Danish Krone
UBS AG
Novo Nordisk A/S
DNK
Hubert Dichtl
Warren Buffet
Thomas Müller
Jo Walton
Show more
21:07 06.11.2024
UBS maintains neutral rating on Siemens Healthineers with 51 euro target
09:04 06.11.2024
ubs maintains sell rating for astrazeneca with target price of 11300 pence
16:47 05.11.2024
UBS lowers BASF price target to 47 euros amid economic challenges
10:46 01.11.2024
UBS lowers Aixtron price target amid delayed market recovery expectations
09:23 01.11.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Global Trade Developments
Global Financial Events
Finance Mergers & Acquisitions
Banking Regulations
Retail and Consumer Goods
Startups & Entrepreneurship
Central Bank Actions
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Government Economic Policies
Market Analysis and Predictions
CEO Changes
Domestic Politics
Government Policies
Workplace Trends
GDP Growth & Recession Forecasts
Financial Scams and Security
Countries:
Companies:
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Barclays PLC
Deutsche Bank Money Market PP
The Goldman Sachs Group, Inc.
Banco Santander, S.A.
Credit Suisse Strategic Income I
Berkshire Hathaway Inc.
Lloyds Banking Group plc
SpaceXCoin USD
Morgan Stanley
Amazon.com, Inc.
UBS Group AG
Bank of America Corporation
Wells Fargo & Company
BNP Paribas SA
NVIDIA Corporation
Bank Frick AG
UniCredit S.p.A.
Currencies:
United States Dollar
Euro
British Pound Sterling
Japanese Yen
Swiss Franc
Indian Rupee
Chinese Yuan
South Korean Won
Canadian Dollar
Vietnamese Đồng
Australian Dollar
Thai Baht
Singapore Dollar
Indonesian Rupiah
New Taiwan Dollar
Mexican Peso
Russian Ruble
Hong Kong Dollar
Offshore Chinese Yuan
New Zealand Dollar
People:
Donald Trump
Elon Musk
Warren Buffett
JD Vance
Sergio Ermotti
Mark Haefele
Robin Leopold
Troy L Rohrbaugh
Jennifer Piepszak
Olivier Calvet
Karoline Leavitt
Ursula von der Leyen
Scott Bessent
Stacey Friedman
George Saravelos
Susan P. Crawford
Francois Xavier Bouvignies
Joseph Spak
Stefan Rauti
Jeff Bezos